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ABSTRACT: A synthetic gene encoding human As(III) S-adenosylmethionine (SAM)
methyltransferase (hAS3MT) was expressed, and the purified enzyme was characterized. The
synthetic enzyme is considerably more active than a cDNA-expressed enzyme using endogenous
reductants thioredoxin (Trx), thioredoxin reductase (TR), NADPH, and reduced glutathione
(GSH). Each of the seven cysteines (the four conserved residues, Cys32, Cys61, Cys156, and
Cys206, and nonconserved, Cys72, Cys85, and Cys250) was individually changed to serine. The
nonconserved cysteine derivates were still active. None of the individual C32S, C61S, C156S, and
C206S derivates were able to methylate As(III). However, the C32S and C61S enzymes retained
the ability to methylate MAs(III). These observations suggest that Cys156 and Cys206 play a
different role in catalysis than that of Cys32 and Cys61. A homology model built on the structure
of a thermophilic orthologue indicates that Cys156 and Cys206 form the As(III) binding site,
whereas Cys32 and Cys61 form a disulfide bond. Two observations shed light on the pathway of
methylation. First, binding assays using the fluorescence of a single-tryptophan derivative indicate
that As(GS)3 binds to the enzyme much faster than inorganic As(III). Second, the major product of the first round of
methylation is MAs(III), not MAs(V), and remains enzyme-bound until it is methylated a second time. We propose a new
pathway for hAS3MT catalysis that reconciles the hypothesis of Challenger ((1947) Sci. Prog., 35, 396−416) with the pathway
proposed by Hayakawa et al. ((2005) Arch. Toxicol., 79, 183−191). The products are the more toxic and more carcinogenic
trivalent methylarsenicals, but arsenic undergoes oxidation and reduction as enzyme-bound intermediates.
■ INTRODUCTION
Arsenic is the most ubiquitous toxic substance in the
environment as the result of geochemical and anthropogenic
exposure.3−6 In humans, arsenic is associated with a broad
range of acute and chronic toxic effects that increase the
lifetime risk of cancer and diabetes as well as cardiovascular and
neurological diseases.7−9 Consequently, arsenic rates first on
the United States Center for Disease Control and Prevention
(CDC) and Environmental Protection Agency’s (EPA) priority
list of hazardous substances (http://www.atsdr.cdc.gov/spl/).
In humans, S-adenosylmethionine As(III) methyltransferase
(hAS3MT, EC 2.1.1.137) catalyzes transfer of methyl groups
from SAM to As(III), producing MAs, DMAs, and traces of
TMAs.10 Human AS3MT is primarily a liver enzyme that is a
member of a large superfamily of methyltransferases that are
involved in many physiological functions.11 In humans, arsenic
methylation paradoxically both detoxifies arsenic and simulta-
neously transforms it into carcinogenic species. Biotransforma-
tion of small molecules into carcinogens is common,12 and
arsenic biomethylation is associated with arsenic-related cancers
by conversion of inorganic arsenic (As(III)) into carcinogenic
trivalent MAs(III) and DMAs(III).2,10,13
To date, the pathway of methylation remains controversial.14
One hypothesis proposed by Challenger is that the enzyme
catalyzes a series of alternating oxidative methylations and
reductions, using S-adenosylmethionine as the methyl donor to
generate the pentavalent products methylarsenate (MAs(V),
dimethylarsenate (DMAs(V)) and a lesser amount of
trimethylarsine oxide (TMAs(V)O).1 The trivalent species
MAs(III), DMAs(III), and TMAs(III) are intermediates but
not products. Most consistent with this hypothesis is that
humans primarily excrete DMAs(V) and to a lesser extent
MAs(V).15,16 However, with careful handling, trivalent
methylated arsenicals can be detected in urine.17,18 More
recently, Hayakawa and co-workers proposed an alternate
pathway in which the preferred substrates of the methyl-
transferase are the glutathione (GSH) conjugates As(GS)3 and
MAs(GS)2, and the products are the trivalent conjugates
MAs(GS)2 and DMAs(GS).
2 In this pathway, there is no
change in the oxidation state of arsenic, which remains trivalent
throughout the catalytic cycle. The conjugates dissociate to
unstable MAs(III) and DMAs(III), which rapidly oxidize
nonenzymatically in air to MAs(V) and DMAs(V), the primary
observed urinary species.18,19
Knowledge of the enzymatic mechanism of AS3MT is critical
for understanding its parallel roles in arsenic detoxification and
carcinogenesis. There have been few biochemical studies with
purified human AS3MT. AS3MT was first purified from rat
liver cytosol by Thomas and co-workers, and the rat and human
genes were subsequently cloned.20−22 The enzyme methylates
inorganic As(III) using SAM as methyl donor and a variety of
reductants, both artificial and natural, including thioredoxin
(Trx) (with an NADPH and thioredoxin reductase (TR)
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regenerating system).17,21,23 Geng et al. expressed the hAS3MT
cDNA in E. coli as a Trx tagged protein.24 However, their
protein had such extremely low activity that an excess of
enzyme (3 μM) over substrate (1 μM As(III)) was required for
extended periods (2 h) to observe methylation. With an excess
of enzyme, there is at most a single turnover and not real
measurement of catalysis. Ding et al. also purified hAS3MT
from a cDNA clone.17 This enzyme was capable of slowly
producing both MAs(III) and DMAs(III), with either Trx or
the artificial reductant tris(2-carboxyethyl)phosphine (TCEP)
supplying reducing potential. In vitro, GSH is not sufficient but
increases methylation in conjunction with Trx.23 The identity
of the physiological electron donors is not clear. Perhaps Trx
and GSH have different roles in the catalytic cycle of AS3MT.
This purified hAS3MT methylates As(III) primarily to
DMAs(V), but, like the other hAS3MT expressed from a
cDNA clone,25 its activity is low. Equimolar enzyme and
As(III) (each at 1 μM) for 2 h was required to transform
As(III) to DMAs(V), so this may also represent only a single
turn over and not sustained catalysis.
The in vitro properties of human AS3MT have not been
systematically analyzed under catalytic conditions but only in
assays with stoichiometric enzyme. We also expressed a cDNA
clone of human AS3MT and purified hAS3MT by heterologous
expression in Escherichia coli.17 However, this preparation of
recombinant enzyme was no more active than those of other
laboratories. To produce a highly active form of human AS3MT
functional in catalytic concentrations and to improve
expression, the hAS3MT gene was chemically synthesized
with codon optimization for E. coli. Codon optimization does
not alter the amino acid sequence of the protein but generally
improves translation, protein folding, and activity.26,27 The
synthetic enzyme exhibited high activity in catalytic concen-
trations. In this study, we examined the catalytic properties of
the synthetic enzyme. Binding of arsenicals to a single-
tryptophan derivative of hAS3MT was estimated from the
quenching of intrinsic protein fluorescence, and the enzyme
appears to bind As(GS)3 preferentially over inorganic As(III).
In addition, MAs(III) was the primary product observed within
the first few minutes of catalysis but remained mostly enzyme-
bound until it was methylated a second time. These results are
consistent with the pathway proposed by Hayakawa and co-
workers and are inconsistent with the Challenger pathway. The
involvement of the four conserved cysteine residues, Cys32,
Cys61, Cys156, and Cys206, was examined by site-directed
mutagenesis. Substitution of any of the four resulted in loss of
ability to methylate As(III), but both the C32S and C61S
derivates could still methylate MAs(III). These results suggest
that only Cys156 and Cys206 are required for all steps in the
methylation pathway and that Cys32 and Cys61 play a different
role in the catalysis. A homology model of hAS3MT based on
the crystal structure of a thermophilic orthologue indicates that
Cys156 and Cys206 form the binding site for As(III) and
MAs(III), whereas Cys32 and Cys61 approach each other
closely enough to form a disulfide bond. We propose that this
disulfide bond forms during the catalytic cycle and that a role of
Trx is to reduce the disulfide and regenerate the active form of
AS3MT.
■ MATERIALS AND METHODS
Reagents. Unless otherwise stated, all reagents were purchased
from Sigma-Aldrich Co. LLC (St. Louis, MO). MAs(V) was reduced
to MAs(III) as described.28 For DNA manipulation, E. coli TOP10 (F−
mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 ΔlacX74 recA1
araD139Δ(araA-leu)7697 galU galK rpsL endA1 nupG) was employed
through out.
Synthesis of the Human AS3MT Gene and Cloning of
hAS3MT cDNA. A hAS3MT gene corresponding to the sequence of
the cDNA clone,22 which lacks the last nine residues of the hAS3MT
sequence, was chemically synthesized with 5′ NcoI and 3′ SalI sites
and with codon optimization for expression in E. coli and subcloned
into the EcoRV site of pUC57-Kan (GenScript, NJ, USA). The
synthetic hAS3MT gene was cloned as an NcoI/SalI digest from
pUC57-Kan-hAS3MT into expression vector pET41a(+) that
produces a fusion with the Schistosoma japonicum glutathione S-
transferase (GST) gene at the 5′ end and eight histidine residues at the
3′ end.
To produce the natural protein, hAS3MT cDNA was generously
provided by M. Styblo, University of North Carolina. The 1.1 kb
fragment was amplified by PCR using forward primer 5′-
CCAGCCATGGCTGCACTTCGTGACGCTGAGA-3′ (NcoI site
underlined) and reverse primer 5′-CCTAGTCGACTCCAGCAG-
CATCAGGGACACATC-3′ (SalI site underlined). The PCR product
was cloned into pBAD-Myc/His-A as an NcoI/SalI digest, generating
plasmid pBAD-hAS3MT in which the gene was fused with a six-
histidine tag at the 3′ end. All sequences were verified by sequencing
the entire gene by Sequetech, CA, USA.
Mutant Construction. Mutations in the AS3MT were introduced
by site-directed mutagenesis using a QuikChange mutagenesis kit
(Stratagene, La Jolla, CA). The oligonucleotides used for mutagenesis
are listed in Table S1. The codons for the conserved Cys32, Cys61,
Cys156, and Cys206 and nonconserved Cys72, Cys85, and Cys250
residues were changed to serine codons, generating seven different
single-cysteine mutants of the synthetic hAS3MT. The double C32S/
C61S mutant was generated by mutating codon 32 in the C61S
derivative to a serine codon. Each mutation was confirmed by
sequencing the entire gene.
Protein Expression and Purification. Wild-type synthetic
AS3MT and its mutants were expressed in E. coli BL21(DE3). Cells
bearing plasmid pET41a-hAS3MT were cultured at 37 °C in 1 L of
Luria Broth medium consisting of 10 g of tryptone, 5 g of yeast extract,
and 10 g of NaCl per liter containing 50 μg/mL kanamycin to mid log
phase (A600nm ∼ 0.5−0.6) before induction with 0.3 mM isopropyl β-
D-1-thiogalactopyranoside (IPTG) for 3 h.29 The induced culture was
centrifuged at 5000 rpm at 4 °C for 15 min, suspended in 20 mL of
buffer A consisting of 50 mM NaH2PO4, pH 8.0, containing 0.3 M
NaCl and 1 mM TCEP to which 10 mM imidazole was added. The
cells were lysed using a French press in the presence of diisopropyl
fluorophosphate and centrifuged at 35 000 rpm for 1 h. The
supernatant was loaded (0.7 mL/min) onto a 5 mL Ni-NTA agarose
column, pre-equilibrated with 5 column volumes of buffer A. The
column was washed (1 mL/min) with 10 column volumes of buffer A
containing 20 mM imidazole, hAS3MT was eluted (0.7 mL/min) with
8 column volumes of buffer A containing 0.25 M imidazole. Imidazole
was removed, and the protein was concentrated to 1 mL by
centrifugation, washing three times with 4 mL of buffer A containing
no imidazole, with Amicon ultra centrifugal filters with 30K membrane
(Millipore, Billerica, MA). Glycerol was added to 20% (v/v), and the
protein was stored in 25 μL aliquots at −80 °C until use. Protein
concentrations were determined from calculated extinction coefficients
at 280 nm.30 The cDNA gene was expressed from E. coli TOP10
bearing pBAD-hAS3MT. The cells were cultured at 37 °C in 1 L of
Luria Broth medium containing 100 μg/mL ampicillin to mid log
phase (A600nm ∼ 0.5−0.6) before induction with 0.2% (w/v) L-
arabinose for 3 h. The natural hAS3MT was purified as described
above. Trx and TR were purified by Ni-NTA chromatography as
described above from E. coli BL21(DE3) carrying either pET14b-trxA
or pET14b-trxB (kindly provided by J. Messens of VIB-Vrije
Universiteit, Brussels, Belgium). All buffers were degassed by bubbling
with argon for 30 min before use.
Arsenic Methylation. Methylation of As(III) and MAs(III) was
assayed both in E. coli expressing AS3MT genes and by purified
proteins. Individual colonies of E. coli strains BL21(DE3) or TOP10
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bearing the appropriate plasmids were inoculated into 2 mL of Luria
Broth medium supplemented with the appropriate antibiotics and
incubated at 37 °C overnight. Late exponential phase cells were diluted
200-fold into 2 mL of Luria Broth medium containing 50 μg/mL
kanamycin, 0.3 mM IPTG, and 20 μM sodium arsenite. After 12 h at
37 °C, the cells were removed by centrifugation, and the supernatant
solution was immediately passed through a 3 kDa cutoff Amicon
ultrafilter (Millipore, Billerica, MA). The filtrate was speciated by high-
pressure liquid chromatography (HPLC) (PerkinElmer Series 2000)
using a C18 reversed-phase column eluted with a mobile phase
consisting of 3 mM malonic acid, 5 mM tetrabutylammonium
hydroxide, and 5% (v/v) methanol (pH 5.9) with a flow rate of 1
mL/min, and arsenic content was determined by inductively coupled
plasma mass spectrometry (ICP-MS) using an ELAN DRC-e
spectrometer (PerkinElmer, Waltham, MA).
Methylation activity of purified AS3MTs was assayed at 37 °C in
buffer B consisting of 50 mM NaH2PO4, pH 8.0, containing 0.3 M
NaCl. Unless otherwise noted, the assays contained 5 mM GSH, 1
mM SAM, 10 μM Trx, 3 μM TR, and 0.3 mM NADPH, and the
reactions were terminated by adding 10% (v/v) H2O2 to oxidize all
arsenic species. Denatured protein was removed by centrifugation
using a 3 kDa cutoff Amicon ultrafilter. The filtrate was speciated by
HPLC-ICP-MS.
Where noted, H2O2 was not added to allow for determination of
trivalent arsenicals. Without oxidation, the majority of the arsenic at
early times was found to be bound to the enzyme. To determine the
nature of AS3MT-bound arsenicals, purified synthetic hAS3MT (5
μM) was incubated at 37 °C with 20 μM As(III) as described above
for 10 min. A portion of the assay mixture was passed through a Bio-
Gel P-6 column pre-equilibrated with buffer B, and then portions (25
μL) were immediately diluted with 6 M guanidine HCl or 8 M urea to
denature protein and release the bound arsenicals, which were
determined as described above.
Fluorescence Assays. hAS3MT has three tryptophan residues at
positions 73, 203, and 213 (numbering is according to the translated
cDNA sequence) (Figure S3). To obtain a single-tryptophan
derivative of hAS3MT, three double-tryptophan mutants were
prepared by changing two of the three tryptophan residues at each
position (Table S2), creating single-tryptophan derivatives Trp73
(W203L/W213Y), Trp203 (W73R/W213Y), and Trp213 (W73R/
W203Y) by site-directed mutagenesis. For removal of the GST tag, the
GST−Trp73 fusion protein was incubated with thrombin (0.7 U/mg
fusion protein) in a buffer consisting of 0.14 M NaCl, 2.7 mM KCl, 10
mM Na2HPO4, 1.8 mM KH2PO4, and 1 mM TCEP, pH 7.3, at 23 °C
for 18 h. Following the cleavage reaction, the Trp73 enzyme was
purified at 4 °C using glutathione sepharose 4B (GE Healthcare, USA)
following manufacturer’s instructions.
Fluorescence measurements were performed on a temperature-
controlled QuantaMaster UV VIS QM-4 steady state spectrofluor-
ometer (Photon Technology International, Birmingham, NJ) at 25 °C.
For steady-state measurements, both emission and excitation
monochromator slits were set at 1 nm. Samples were excited at 295
nm to excite tryptophan, and emission was set at 336 nm for time-
based data acquisition. Spectra were corrected for background
fluorescence and Raman scattering by subtracting buffer spectra. The
buffer used was 50 mM MOPS and 0.5 M NaCl, pH 7.5. For
determination of relative binding of free metalloids, As(III) and
MAs(III), and preformed GSH conjugates, fluorescence spectra were
acquired at the indicated concentrations of arsenicals in the presence
and absence of GSH. To obtain binding rates, time-based fluorescence
quenching data were fitted to a single exponential decay isotherm
using Prism 6 (GraphPad Software Inc.).
Homology Model of the hAS3MT Structure. A homology
model of hAS3MT was built on the structure of PhAs(III)-bound
CmArsM (PDB ID: 4KU9) using a fully automated protein structure
homology modeling server SWISS-MODEL (http://swissmodel.
expasy.org/).31 The four conserved cysteine residues (Cys32, Cys61,
Cys156, and Cys206) (residue numbers are based on the hAS3MT
sequence) are present in the model structure. The model quality was
estimated on the basis of the QMEAN scoring function.32 The model
structure with residues 44−371 (residue numbers are based on the
CmArsM sequence) from PhAs(III)-bound CmArsM was used as a
template, and the final homology model incorporated 308 of those 328
residues. In silico docking with SAM was carried out using the
PATCHDOCK server.33 The docked hAS3MT model with SAM was
superimposed with the As(III)-bound structure of CmArsM (PDB ID:
4FSD) to acquire the arsenic atom in the As(III) binding site of
hAS3MT.34 PyMOL v1.3 was used to visualize the structural
models.35,36
■ RESULTS
Chemical Synthesis of hAS3MT. In two prior studies,
human AS3MT was expressed from a cDNA clone and purified
after heterologous expression in E. coli.20,24 In both cases,
methylation was assayed using molar ratios of AS3MT/As(III)
of either 1:1 or 3:1 for extended periods of time.17,24 With
stoichiometric or higher ratios of enzyme to substrate, not more
than a single cycle of methylation is possible, so it is not know
whether either construct could attain steady state, the most
commonly used approach to enzyme kinetics.37 We took a
different approach to the generation of purified AS3MT that
could work at catalytic rather than stoichiometric concen-
trations.
The sequence of the cDNA that had been used by others to
produce hAS3MT was chemically synthesized. The key feature
of the chemical synthesis was an increase in the codon usage
bias for E. coli by upgrading the codon adaptation index from
0.64 to 0.88. In addition, the GC content was optimized, and
stem-loop structures were disrupted to increase ribosome
binding and the half-life of the mRNA. The stem-loop
structures, which impact ribosomal binding and stability of
mRNA, were broken. The final product has a total of 662
residues with 366 of the AS3MT residues unchanged from the
cDNA sequence, a fusion with glutathione S-transferase at the
N-terminus to improve solubility including tandem thrombin
and enterokinase sites, and eight histidines at the C-terminus
for purification. The changes in the synthetic sequence from
that of the cDNA sequence are highlighted in Figure S1, and
the sequence of the protein is shown in Figure S2.
Binding of Trivalent Arsenicals to Synthetic hAS3MT.
Intrinsic tryptophan fluorescence has been extensively exploited
in examining arsenic binding in arsenic detoxification
proteins.28,38−41 hAS3MT has three tryptophan residues at
positions 73, 203, and 213 (Figure S3). To obtain a single-
tryptophan derivative of hAS3MT, three double-tryptophan
mutants were prepared by changing two of the three
tryptophan residues at each position (Table S2), creating
single-tryptophan derivatives Trp73 (W203L/W213Y), Trp203
(W73R/W213Y), and Trp213 (W73R/W203Y). The GST tag,
which contains four tryptophan residues, was removed by
thrombin cleavage, as described in the Materials and Methods.
Of the three single-tryptophan derivatives, only the Trp73
derivative reported binding of arsenicals with a quenching of
protein fluorescence. The observed rate of quenching by
preformed As(GS)3 to hAS3MT was faster than could be
measured accurately with our fluorometer (Figure 1A, curve 5).
The fluorescence signal slowly increased, but addition of GSH
to the buffer stabilized the quenching (Figure 1A, curve 6). We
interpret this result as the As(GS)3 complex dissociating when
diluted into the assay buffer, and that GSH in the buffer
prevents dissociation. In contrast, the rate of quenching with
inorganic As(III) was extremely slow (Figure 1A, curve 3),
requiring approximately 10 min to produce the same quenching
as that produced by As(GS)3 in 1 s, but the quenching by
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As(III) could be accelerated by addition of GSH to the buffer
(Figure 1A, curve 4), which we interpret as conjugate formation
in the assay buffer. When the quenching of tryptophan
fluorescence was fitted to a single exponential decay isotherm,
the rate with inorganic As(III) in buffer containing GSH
(Figure 1A, curve 4) was approximately 130-fold faster than the
rate in the absence of GSH (Figure 1A, curve 3).
Similar results were observed with addition of either
MAs(III) or MAs(GS)2. Fluorescence quenching with MAs-
(III) (Figure 1B, curve 3) was slow compared to that with
MAs(GS)2, but it was faster than with inorganic As(III).
Fluorescence quenching could be accelerated by addition of
GSH to the buffer (Figure 1B, curve 4), which was similar to
quenching with preformed MAs(GS)2 (Figure 1B, curve 5), but
both were too fast to quantify. Clearly, binding of glutathione
conjugates is extremely rapid, but detailed rate determinations
will require stopped-flow analysis.
Catalytic Properties of Synthetic AS3MT. Initial studies
investigated methylation of As(III) by hAS3MT in reaction
mixtures in which physiological and nonphysiological reduc-
tants were employed. Under all conditions, As(III) was
methylated to both MAs and DMAs, but the extent of
methylation and the ratio of DMAs/MAs varied (Figure 2). In
these assays, no differentiation was made between trivalent and
pentavalent products because the reactions were terminated by
addition of H2O2, which oxidizes all arsenicals to their
pentavalent forms. As described below, this was necessary
because a significant percentage of the total arsenic remained
bound to the enzyme. Following oxidation with peroxide, all of
the arsenic could be recovered. In human populations,
individuals with higher conversion to DMAs have lower rates
of bladder cancer and other arsenic-related diseases.42 MAs(III)
is considered to be more toxic than DMAs(III), and a higher
fraction of MAs excreted in urine correlates with arsenic-related
diseases.16,19,42 People with more rapid methylation to DMAs
may have more rapid clearance and be less susceptible to
diseases. On the basis of those considerations, we define
optimal hAS3MT activity as conditions that resulted (1) in the
greatest total methylation and (2) produced the highest ratio of
DMAs to MAs. Under the conditions employed, hAS3MT
showed the highest activity with the combination of cysteine
and the artificial reductant TCEP. Note that nearly all of the
As(III) was methylated with an As(III)/hAS3MT ratio of 10,
the first example of multiple rounds of catalysis by purified
hAS3MT. With possible physiological reductants, GSH alone
produced the lowest activity. High activity was observed with
addition of purified Trx plus a Trx-regenerating system
consisting of NAPH and TR (termed the Trx system). With
the Trx system, the DMAs/MAs ratio was similar to that with
TCEP alone (5.5−7.3). Addition of GSH to either TCEP or
Figure 1. Effect of As(GS)3 and MAs(GS)2 on the fluorescence of
Trp73 hAS3MT. Following removal of the GST tag, intrinsic protein
fluorescence of Trp73 hAS3MT was assayed at 25 °C in degassed
buffer, as described in the Materials and Methods. As noted, 5 mM
GSH was added to the buffer. Excitation and emission wavelengths
were 295 and 336 nm, respectively. Metalloids were added at a
concentration of 1 mM to 1 μM Trp73 hAS3MT. (A) Quenching by
inorganic arsenicals. Additions: curve 1, no addition; curve 2, As(V);
curve 3, As(III); curve 4, As(III) with GSH in the buffer; curve 5,
As(GS)3; curve 6, As(GS)3 with GSH in the buffer. (B) Quenching by
methylated arsenicals. Additions: curve 1, no addition; curve 2,
MAs(V); curve 3, MAs(III); curve 4, As(GS)3 with GSH in the buffer;
curve 5, MAs(GS)2 with GSH in the buffer.
Figure 2. Effect of reductants on methylation of As(III) by synthetic
hAS3MT. The reaction containing 1 μM hAS3MT, 1 mM SAM, 10
μM As(III), and the indicated reductants was incubated for 90 min at
37 °C. The reactions were terminated by addition of 10% (v/v) H2O2
to oxidize all arsenic species, which were speciated by HPLC-ICP-MS.
Reductants (final concentrations): 5 mM GSH, 5 mM cysteine, 1 mM
TCEP, 10 μM Trx (+ 3 μM thioredoxin reductase and 0.3 mM
NADPH), or mixtures of those as indicated. Open bars (left),
inorganic arsenic; left-slanted bars (middle), MAs; right-slanted bars
(right), DMAs. The data are the mean ± SE (n = 3).
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the Trx system both increased total methylation and the
DMAs/MAs ratio (7.0−11.7). Thus, GSH is not a particularly
good reductant but might play a different role than Trx, such as
forming the As(GS)3 substrate.
2
Precursor−Product Relationship of hAS3MT Methyl-
ation. The time course of As(III) methylation over a 3 h
period was determined using GSH and the Trx system (Figure
3A). The production of MAs was linear over the first 10 min,
reaching a plateau at 30 min and decreasing to nearly zero after
180 min. At this point, MAs accounted for approximately about
15% of the total arsenic in the reaction mixture. The production
of DMAs had a lag of approximately 10 min and then increased
until 97% of the total arsenic was present as DMAs. These
results are consistent with the Briggs−Haldane steady-state
assumption of enzyme catalysis, which predicts a precursor−
product relationship for an irreversible reaction.37 In this case,
the immediate product is MAs, which disappears as it is
converted to the major product DMAs. Under similar
conditions, the native enzyme from the cDNA construct
exhibited little methylation activity (Figure 3B). When both
synthetic and native enzyme were present at catalytic
concentrations (1 μM enzyme and 10 μM As(III)), little
DMAs was produced by the native enzyme after 2 h, compared
with 80% conversion with the synthetic enzyme. Thus, the
synthetic enzyme is active when present in catalytic
concentrations, whereas the purified native enzyme is not.
Although we cannot eliminate other possibilities, a logical
inference is that they differ in conformation, perhaps because
the native enzyme does not fold as well as the synthetic
enzyme, which was optimized for E. coli expression. One
possible explanation is that the native gene has a total of 17 rare
codons for Arg, Leu, Ile, and Pro that were corrected in the
synthetic gene. That could slow the rate of translation and
hence the rate of folding of the native protein.
Figure 3. As(III) methylation by synthetic and native hAS3MTs. The reaction mixture (1.5 mL) containing 1 μM of either purified synthetic (A) or
native (B) hAS3MT, 1 mM SAM, 5 mM GSH, 10 μM Trx, 3 μM TR, 0.3 mM NADPH, and 10 μM As(III) was incubated at 37 °C. Samples were
withdrawn at the indicated times, and the reaction terminated by addition of 10% (v/v) H2O2, final concentration, and analyzed by HPLC-ICP-MS.
The data are the mean ± SE (n = 3).
Figure 4. MAs(III) forms an enzyme-bound intermediate. (A) Formation of soluble MAs(III). Purified hAS3MT (1 μM) was incubated at 37 °C
with 10 μM As(III) containing 5 mM cysteine and 1 mM SAM for the indicated times. Protein was removed, and the soluble arsenicals were
speciated by HPLC-ICP-MS. (B) Formation of enzyme-bound MAs(III). Purified hAS3MT (5 μM) was incubated at 37 °C with 20 μM As(III)
containing 5 mM GSH, 1 mM SAM, 10 μM Trx, 3 μM TR, and 0.3 mM NADPH. After 10 min, samples were separated through a Bio-Gel P-6 spin
column. Portions (25 μL) were diluted with 6 M guanidine HCl or 8 M urea to final concentrations of 4 M to denature the protein and release the
enzyme-bound arsenicals, which were analyzed by HPLC-ICP-MS.
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The Initial Product of the Methylation Reaction Is
Trivalent and Remains Bound to the Enzyme. After 10
min at 37 °C, synthetic hAS3MT methylated As(III) to soluble
MAs(III), with little MAs(V) observed (Figure 4A). These
results support the postulate of Hayakawa et al. that the
products of hAS3MT are trivalent, not pentavalent.2 However,
at early times the majority of the arsenic appeared to be
insoluble, and we predicted that it is bound to the enzyme. To
examine this possibility, As(III) methylation was carried out for
10 min with concentrations of enzyme (5 μM) and As(III) (20
μM) higher than in the usual assay conditions to obtain
sufficient enzyme-bound form. Unbound arsenic was removed,
and the protein with bound arsenicals was denatured with
guanidine HCl or urea to release the protein-bound arsenicals
(Figure 4B). When a protein is denatured with guanidine HCl
or urea, it is unfolded, disrupting the secondary and tertiary
structures. Because substrate binding sites in enzymes are
composed of amino acid residues that are brought together in
precise distances and geometries, unfolding of the protein will
destroy the binding site and release noncovalently bound
ligands. Denatured protein was removed by filtration, and the
filtrate was speciated by HPLC-ICP-MS. MAs(III) was the
major bound arsenical form released from the enzyme. A small
amount of MAs(V) was also observed, but in control assays, a
similar amount of MAs(III) was nonenzymatically oxidized to
MAs(V).
Effect of Substitution of Conserved Cysteine Residues
on hAS3MT Activity. As(III) SAM methyltransferases have
four conserved cysteine residues (Figure S3), Cys32, Cys61,
Cys156, and Cys206, in hAS3MT.28,43 The cDNA clone lacks
the last nine residues of the actual hAS3MT sequence,
including three cysteine residues, but there are seven other
nonconserved cysteines (Cys72, Cys85 Cys226, Cys250,
Cys271, Cys334, and Cys360). Of these nonconserved
residues, Cys72, Cys85, and Cys250 were altered to serine
residues, and cells expressing the C72S, C85S, and C250S
derivatives retained the ability to methylate As(III) (Figure
5A). When the conserved cysteines were altered to serine
residues, and cells expressing the C32S, C61S, C156S, and
C206S derivatives did not methylate As(III) (Figure 5A). The
C32S, C61S, C156S, C206S, and C32S/C61S derivatives were
expressed, and the activity of the purified enzymes examined.
None of the altered proteins was able to methylate inorganic
As(III) even after 3 h (Figure 5B). In contrast, C32S and C61S
retained the ability to methylate MAs(III) (Figure 6), whereas
neither C156S nor C206S were able to do so (data not shown).
Although the results of mutagenesis are always open to
interpretation, these observations indicate that Cys156 and
Cys206 are essential for both the first and second cycles of
methylation, whereas Cys32 and Cys61 are required for the first
methylation but not the second. Thus, there appears to be two
classes of cysteine residues: Cys32 and Cys61 in one class and
Cys156 and Cys206 in the other.
A Homology Structural Model of hAS3MT. A homology
model of hAS3MT model was built on the CmArsM structure
with bound PhAs(III) (PDB ID: 4KU9) using the SWISS-
MODEL fully automated protein structure homology modeling
server (http://swissmodel.expasy.org/) (Figure 7).31 The
model quality was estimated on the basis of a qualitative
model energy analysis scoring function of 0.64, which is within
the acceptable range.32 The homology model incorporated 308
of 328 residues from 4KU9. The secondary structural
arrangement of hAS3MT was nearly the same as that of the
CmArsM structure, with equivalent metalloid and SAM binding
elements. In silico docking with SAM was carried out using the
program PATCHDOCK.33 This model was superimposed with
the As(III)-bound structure of CmArsM (PDB ID: 4FSD) to
place an arsenic atom in the As(III) binding site of hAS3MT,
and PyMOL v1.3 was used to visualize the structural
model.36,43 Although only a model, it is instructive and
provides testable predictions. The biochemical data demon-
strate that the C-terminal pair of conserved cysteine residues
(Cys156 and Cys206) are involved in methylation of both
As(III) and MAs(III). The N-terminal conserved cysteine pair
(Cys32 and Cys61) is involved in As(III) methylation but not
MAs(III) methylation, suggesting a more subtle role in the
Figure 5. Role of cysteine residues in methylation of As(III). (A) In vivo methylation of As(III) by wild-type and mutant hAS3MTs. E. coli
BL21(DE3) cells bearing vector pET41a(+) or plasmids with wild-type or cysteine mutant genes in pET41a-hAS3MT were grown in 2 mL of Luria
Broth medium in the presence of 20 μM As(III), 0.3 mM IPTG, and 50 μg/mL kanamycin at 37 °C for 12 h. (B) Methylation of As(III) by purified
wild-type and mutant hAS3MTs. Methylation of As(III) was assayed at 37 °C after 3 h with 10 μM As(III), 1 μM hAS3MT, 1 mM SAM, 5 mM
GSH, 10 μM Trx, 3 μM TR, and 0.3 mM NADPH.
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catalytic cycle. In the model, Cys156 and Cys206 form an
As(III) binding site, with the arsenic atom 2.2 and 2.3 Å from
the sulfur atoms of Cys156 and Cys206, respectively. In
contrast, Cys32 and Cys61 are oxidized in a disulfide bond. The
methyl group of SAM was oriented toward the bound As(III) at
approximately 3.9 Å distance.
A Disulfide Bond Cascade Reaction Mechanism for
hAS3MT. On the basis of a combination of experimental data
and structural modeling, we propose a novel reaction scheme
involving a disulfide bond cascade with at least two sequential
disulfide bonds: the first between Cys32−Cys61 and the
second between Cys61−Cys156 (Figure 8), based on the
disulfide bonds observed in the crystal structures of the
Cyanidioschyzon merolae orthologue (PDB IDs: 4KU9 and
4FR0). The catalytic cycle for the first two rounds of
methylation can be summarized in eight steps. (1) In the first
round of methylation, hAS3MT binds As(III) in a series of
three thiol transfer reactions from As(GS)3, which is the
preferred substrate (Figure 1). (2) The methyl group of SAM is
attacked by the arsenic lone pair, (3) which leads to formation
of a transient positively charged pentavalent MAs(V)
intermediate.44 (4) The role of Cys32 (or Cys61; at this
time, we cannot distinguish between them) is to provide
electrons to reduce enzyme bound MAs(V) to MAs(III) and to
allow the next round of methylation. By donating electrons to
the arsenic, Cys32 (or Cys61) becomes oxidized, forming a
disulfide bond with Cys61. (5) The role of Trx is to reduce the
disulfide bond, consistent with the traditional role of
thioredoxins in facilitating reduction of protein cysteine
disulfides by thiol−disulfide exchange. Oxidized Trx is reduced
by TR with electrons from NADPH. MAs(III) remains strongly
bound by the thiol pair Cys61−Cys156. The disulfide bond is
reduced with Trx, and (6) the enzyme undergoes the next
round of methylation, forming a transient positively charged
pentavalent DMAs(V) intermediate, (7) which is reduced to
DMAs(III) by Cys61, forming a Cys61−Cys156 disulfide. (8)
The disulfide is reduced by Trx, regenerating the enzyme and
releasing the major soluble product, DMAs(III). Finally, in
Figure 6. Role of cysteine residues in methylation of MAs(III). Methylation of MAs(III) by cysteine mutants was assayed at the indicated times at 37
°C with 10 μM MAs(III), 1 μM hAS3MT, 1 mM SAM, 5 mM GSH, 10 μM Trx, 3 μM TR, and 0.3 mM NADPH. The reaction was terminated by
addition of 10% (v/v) H2O2, final concentration. Protein was removed before analysis, and soluble arsenicals were analyzed by reversed-phase
HPLC-ICP-MS. (A) Synthetic wild-type hAS3MT. (B) C32S mutant. (C) C61S mutant. (D) C32S/C61S double mutant. The C156S and C206S
derivatives did not methylate MAs(III) (not shown).
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urine, exposure to air nonenzymatically oxidizes DMAs(III) to
DMAs(V). Thus, the substrates and products are all trivalent, as
predicted by Hayakawa et al., but the arsenic undergoes a cycle
of oxidation and reduction, as hypothesized by Challenger, but
only when it is enzyme-bound. GSH and Trx are involved, but
not as reductants of pentavalent intermediates. Instead,
As(GS)3 serves as the arsenic donor to the enzyme, as
hypothesized by Hayakawa et al., and Trx is a protein disulfide
reductase.45 Advantages of this pathway are that it explains
current results with As(III) SAM methyltranferases and
reconciles the proposals of Challenger and Hayakawa et al.
■ DISCUSSION
Arsenic is clearly a health hazard, but is it inorganic or
methylated arsenicals that produce the risk? The answer
depends in large part on the products of AS3MT, the enzyme
Figure 7. Homology structural model of human AS3MT. The cartoon diagram representation of human AS3MT model structure is colored in tan.
The location of four conserved Cys residues are shown along with the bound SAM and As(III). The expanded view shows the four conserved
cysteine residues (in ball-and-stick), with Cys32 and Cys61 in a disulfide bond and Cys156 and Cys206 binding the As (blue ball) atom. SAM (in
ball-and-stick) occupies its binding site with its methyl group (*) poised to be donated to the arsenic atom.
Figure 8. Proposed hAS3MT reaction scheme: (1) In the first round of methylation, hAS3MT binds As(III) in a series of three thiol transfer
reactions from As(GS)3; (2) the methyl group of SAM is attacked by the arsenic lone pair; (3) a pentavalent MAs(V) intermediate is formed and (4)
reduced to an enzyme-bound MAs(III) intermediate by Cys32 with formation of a Cys32−Cys61 disulfide; (5) the disulfide is reduced with Trx, and
the enzyme undergoes the next round of methylation, (6) forming a pentavalent DMAs(V) intermediate, (7) which is reduced to DMAs(III) by
Cys61. This form is a Cys61−Cys156 disulfide, which (8) is reduced by Trx, regenerating the enzyme and releasing the major soluble product,
DMAs(III). Finally, in air, trivalent DMAs(III) is nonenzymatically oxidized to DMAs(V).
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that methylates arsenic in liver and other organisms. There are
two schools of thought on this matter. The original proposal by
Challenger in the 1940s involved a series of oxidative
methylations such that the substrates were trivalent arsenicals
and the products were pentavalent.1 A more recent proposal by
Hayakawa et al. suggests that both the substrates and products
are trivalent, a key difference between the two major
proposals.2 If Challenger is correct, then the products are
relatively nontoxic and noncarcinogenic. If Hayakawa et al. is
correct, then the products are more toxic and carcinogenic than
the inorganic As(III) substrate.
Challenger was ahead of his time since nothing was known of
the very large superfamily of methyltransferase enzymes in the
1940s. Members of that superfamily append a methyl group
from SAM to acceptor groups by SN2 displacement
mechanisms, involving attack of a nucleophile on the methyl
group of SAM with inversion of configuration and concomitant
release of SAH.11 Methyltransferases are categorized on the
basis of the electron-rich, methyl-accepting atom, usually O, N,
C, or S. These enzymes have been studied in exquisite detail for
more than 50 years. They all have a conserved SAM binding
fold and use a common enzymatic mechanism of methyl-
transfer, where SAM serves as a potent alkylating agent with
destabilization of the sulfonium ion. While Challenger
proposed a series of oxidations and reductions along with
three rounds of methylations, none of the O-, N-, C- and S-
methyltransferases oxidizes their substrates, and no one has
demonstrated the presence of a pentavalent arsenic inter-
mediate bound to AS3MT or its orthologues. The evidence that
AS3MT directly generates As(V) metabolites is not strong.
Lysine and arginine methyltransferases are good models for
arsenic methyltransferases, as they carry out three very similar
methyl transfers without oxidation of the nitrogen. In summary,
methyltransferases methylate their substrates without oxidation.
Nature is conservative, and there is no reason to consider that
AS3MT would use a different enzymatic mechanism from that
of any other member of the superfamily.
Yet, a major chemical difference between the metalloid
arsenic and the nonmetal atoms (O, N, C, S) acceptors of the
methyl group is its redox activity. For that reason, there is the
possibility that As(III) in the metalloid binding site of hAS3MT
becomes oxidized during the catalytic cycle and is reduced
again by donation of electrons from the conserved cysteine
residues. Thus, we propose the formation of the transient
pentavalent intermediates shown in steps 3 and 6 of our
proposed reaction cycle (Figure 8). However, it is not clear if
pentavelent intermediates are obligatory components in the
mechanism or side reactions that are the consequences of
oxidation. Regardless of whether AS3MT catalyzes alternation
between reduced substrates and oxidized intermediates,
transient trivalent intermediates are likely to be easily oxidized,
and there must be a mechanism to keep them reduced. In
either case, the disulfide bond cascade that takes place using the
conserved cysteine residues of AS3MT is a novel feature of
As(III) SAM methyltransferases that differentiates it from other
members of the methyltransferase superfamily.
Another prediction of Hayakawa et al. is that the substrate is
As(GS)3 and not free inorganic arsenic. This is very reasonable
because GSH, the major thiol in cells, is present at millimolar
concentrations and reacts readily with As(III) to form the
triglutathione complex inside cells.46 Some microorganisms use
thiols other than GSH as their major intracellular reductant.47
Although we have no data on methylation in any of those
organisms, we can predict that they will be able to use other
As−thiol conjugates. Dithiols can readily abstract As(III) from
As(GS)3, so it is also reasonable that As(GS)3 is able to donate
As(III) to conserved cysteine residues in hAS3MT.48 The
As(GS)3 complex is unstable in vitro, so it is challenging to
observe its interaction with enzymes. Quenching of intrinsic
protein fluorescence by arsenicals in single-tryptophan
derivatives has been shown to reflect binding.28,41 Using
single-tryptophan derivates, we examined the transfer of As(III)
from As(GS)3 to the binding site in the ArsD metallochaperone
and the CmArsM orthologue of hAS3MT. We took a similar
approach with hAS3MT by introduction of a single tryptophan,
Trp73, adjacent to the predicted As(III) binding site. The
results are striking: free inorganic As(III) binds over a period of
minutes, whereas preformed As(GS)3 binds in seconds.
Similarly, MAs(GS)2 bound faster than MAs(III). An enzyme
that takes minutes to bind its substrate is not a very useful
catalyst. If As(III) was added to GSH-containing buffer,
quenching was enhanced relative to that with GSH-free buffer,
indicating formation of the conjugates during the course of the
assay. Even As(GS)3 quenched fluorescence faster when the
buffer contained GSH, suggesting that the conjugate dissociates
when diluted into GSH-free buffer but is stabilized when the
buffer contains GSH. These results are most consistent with the
glutathione conjugates of inorganic and methylated arsenicals
serving as the source of arsenic for hAS3MT.
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